Neurontin shortage — IE supply status & alternatives

Neurontin

—

🇦🇺 AUST R 66005 · Mylan Health Pty Ltd

In supply · Australia

In supply · 🇦🇺 Australia · short in🇮🇪 IE

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Neurontin
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No
Marketing-authorisation holders	Mylan Health Pty Ltd, UPJOHN UK LIMITED, VIATRIS PRODUCTS LIMITED, Parke-Davis Div of Pfizer Inc +1 more

Registrations on file	17

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇺🇸 US

US$7.39

Acquisition

🇫🇷 FR

€29.40

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 3 resolved events

◷

0–3 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇮🇪

Ireland

HPRA · 1d ago

Medium

🇪🇸

Spain

AEMPS · 1d ago

Resolved

Verified timeline regulator events

🇮🇪 8 June 2026

medium reported

🇪🇸 5 Apr 2026

Shortage resolved

🇪🇸 5 Nov 2025

Shortage resolved

🇪🇸 4 Sept 2025

Shortage resolved

Sources official regulators

🇮🇪

HPRA

verified 1d ago

verify ↗

🇪🇸

AEMPS

verified 1d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders17 registrations · 5 MA holders

Product	Strength	Form	Market	MA holder	Status
NEURONTIN gabapentin	400mg	—	🇦🇺 AU	Mylan Health Pty Ltd	Active
NEURONTIN gabapentin	300mg	—	🇦🇺 AU	Mylan Health Pty Ltd	Active
NEURONTIN 400MG HARD CAPSULES	400MG	capsule	🇬🇧 GB	UPJOHN UK LIMITED	Active
NEURONTIN 600MG FILM-COATED TABLETS	600MG	tablet	🇬🇧 GB	UPJOHN UK LIMITED	Active
NEURONTIN 800MG FILM-COATED TABLETS	800MG	tablet	🇬🇧 GB	UPJOHN UK LIMITED	Active
NEURONTIN 100MG HARD CAPSULES	100MG	capsule	🇬🇧 GB	VIATRIS PRODUCTS LIMITED	Active
NEURONTIN 300MG HARD CAPSULES	300MG	capsule	🇬🇧 GB	VIATRIS PRODUCTS LIMITED	Active
Neurontin	800mg/1	tablet	🇺🇸 US	Parke-Davis Div of Pfizer Inc	Discontinued
Neurontin	600mg/1	tablet	🇺🇸 US	Parke-Davis Div of Pfizer Inc	Discontinued
Neurontin	100mg/1	capsule	🇺🇸 US	Parke-Davis Div of Pfizer Inc	Discontinued
Neurontin	300mg/1	capsule	🇺🇸 US	Parke-Davis Div of Pfizer Inc	Active
Neurontin	400mg/1	capsule	🇺🇸 US	Parke-Davis Div of Pfizer Inc	Discontinued
Neurontin	250mg/5mL	solution	🇺🇸 US	Parke-Davis Div of Pfizer Inc	Discontinued
NEURONTIN gabapentin	800mg	—	🇦🇺 AU	Mylan Health Pty Ltd	Active
NEURONTIN gabapentin	600mg	—	🇦🇺 AU	Mylan Health Pty Ltd	Active

+2 more registrations on file

Mederti Drug Report

Generated 6 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.